Walgreens (WBA) Stock Climbs on Rite Aid Deal Asset Sale

Getty Images

Walgreens Boots Alliance is the largest retail pharmacy, health and daily living destination in the U.S. and Europe and, together with its equity method investments*, employs more than 370,000* people and has a presence in more than 25* countries. The next fiscal year earnings is scheduled to be released on 2017-05-09.

Latest analyst recommendations could offer little help to investors.

Walgreens Boots Alliance (WBA) is the first global pharmacy-led, health and wellbeing enterprise. (NASDAQ:WBA) after beginning at $81.82, closed at $82.88 by building up +1.52% in recent trading session. Over the same time span, the stock notched a high price of US$95.74 and its minimum level reached was US$71.5. (NASDAQ:EA) has a consensus rating of 1.47. The debt-to-equity ratio (D/E) was recorded at 0.44. He writes articles for Analysis of different Companies including news and analyst rating updates. Following the completion of the transaction, the director now owns 26,690 shares in the company, valued at approximately $2,171,231.50. The Company's products are marketed under a number of brands, which include No7, the Botanics range, Almus (generic medicines), Boots Pharmaceuticals and Soap & Glory (bathing and beauty brand). The company had revenue of $29498.00 million for the quarter, compared to analysts expectations of $29719.29 million. The institutional ownership stake in the corporation is 61.40% while the Beta value stands at 1.02. Bank of America Corp. restated a "buy" rating on shares of Walgreens Boots Alliance in a report on Monday, June 13th. The stock has received "OVERWEIGHT" rating after consensus analysis from analysts. "Underperform" verdict was shared by 0 analyst and "Overweight" recommendation was issued by 9 analyst. This number is based on a scale from 1 to 5.